




**DRIVE Annual Forum is a unique opportunity
to engage with DRIVE associate partners,
collaborators and stakeholders**





“Brand-specific influenza vaccine effectiveness and COVID-19 impact: how to be better prepared for the 2020/21 season”



DRIVE ANNUAL FORUM WEBINARS 2020

September 22 & September 24, 2020
A Virtual Meeting



DAY 1 – TUESDAY, SEPTEMBER 22, 2020: 3 pm to 5:30 pm CET

“2019/20 Season: Brand Specific Influenza Vaccine Effectiveness and COVID-19

Impact: How to be Better Prepared for the Next Season 2020/2021”

15:00-15:20	Welcome and agenda (1) 2019/20 season: DRIVE achievements and lessons learnt
15:20-15:45	2019/20 season: DRIVE sites experience with COVID-19 pandemic and study management (2) Q&A session: 10 minutes
15:45-16:35	2019/20 season: DRIVE Brand-specific influenza vaccine effectiveness results and COVID-19 impact (3) Q&A session: 20 minutes
16:35-16:55	ECDC management of COVID-19 surveillance in EU: impact on influenza surveillance and status update (4) Q&A session: 10 minutes
16:55-17:20	2020/21 season: DRIVE study platform scale-up and adaptation for COVID-19 (5) Q&A session: 15 minutes
17:20-17:30	Closure and Announcement of next Webinar (6)

(10)(2e)

(10)(2e)

(10)(2e)

(10)(2e)

(10)(2a)

(10)(2e)

(10)(2e)

(10)(2e)

www.drive-eu.org



The DRIVE Project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 777363. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation and EFPIA



“Building on existing influenza infrastructure to monitor and evaluate future COVID-19 vaccines”



DRIVE ANNUAL FORUM WEBINARS 2020

September 22 & September 24, 2020
A Virtual Meeting



DAY 2 – THURSDAY, SEPTEMBER 24, 2020: 3 pm to 5:15 pm CET

“Building on existing influenza infrastructure to monitor and evaluate future COVID-19 vaccines”

15:00-15:10 **Welcome, agenda and brief summary of previous webinar (7)**

15:10-15:30 **EMA Expectations for an EU Post-Marketing Platform for Vaccines Effectiveness Evaluation (8)**

Q&A session: 10 minutes

15:30-15:50 **ACCESS Project Update and DRIVE Contribution (9)**

Q&A session: 10 minutes

15:50-16:10 **FDA views on RWE on Vaccine Effectiveness (10)**

Q&A session: 10 minutes

16:10-16:40 **DRIVE assets for the future**

Public-private collaboration, COVID-19 brand specific vaccines effectiveness & Open data strategy (11)

Impact of joint influenza/COVID-19 vaccination on the vaccine effectiveness estimates from TND studies (12)

Joint Q&A session: 10 minutes

16:40-17:10 **Roundtable session (13)**

(10)(2e) (10)(2e)
(10)(2e)

(10)(2e) (THL)

17:10-17:15 **Closing Remarks (14)**

www.drive-eu.org



The DRIVE Project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 777363. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation and EFPIA